Sai Gastroenterologist Proctology
Welcome,         Profile    Billing    Logout  
 8 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Misselwitz, Benjamin
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
SwissGut, NCT06191224: - The Healthy Swiss Microbiome

Recruiting
N/A
200
Europe
Benjamin Misselwitz
Healthy
07/25
07/25
NCT04976686: Low Carbohydrate Small Intestine Study

Terminated
N/A
13
Europe
Diet modification
Insel Gruppe AG, University Hospital Bern
Diet, Healthy
11/24
11/24
BeBiCo, NCT04447742: Bern Birth Cohort / Trajectory of Microbiota Maturation in Healthy Bern Infants - a Network Approach

Recruiting
N/A
250
Europe
Insel Gruppe AG, University Hospital Bern, University of Bern
Maturation of the Healthy Infant Intestinal Microbiota, Microbial Colonization, Nutrition Disorder, Infant, Milk Expression, Breast, Mental Health Disorder
03/28
03/35
NCT05800704: Support of Colonization Resistance of the Gut Microbiota with the Synbiotic Food Supplement Nagasin®

Active, not recruiting
N/A
49
Europe
Nagasin, maltodextrin
University of Zurich, Insel Gruppe AG, University Hospital Bern, Stadtspital Zürich, Kantonsspital Winterthur KSW, Luzerner Kantonsspital, Cantonal Hosptal, Baselland
C. Difficile Enteritis
03/25
03/25
NCT04978077: Networks of Bacterium-Metabolite Interactions in the Small Intestine

Terminated
N/A
120
Europe
Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)
Insel Gruppe AG, University Hospital Bern
Diet, Healthy, Microbial Colonization
11/24
11/24
COMMIT, NCT05702879: Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

Recruiting
N/A
240
Europe
Ozanimod, TNF Inhibitor, infliximab, adalimumab, etanercept, golimumab, and certolizumab., Steroids, Prednisolon, Vedolizumab, Ustekinumab
Insel Gruppe AG, University Hospital Bern, Bristol-Myers Squibb
Ulcerative Colitis
01/25
01/25
NCT04482452: Percentage Visualized Mucosa as a Marker for the Quality of Colonoscopy

Recruiting
N/A
500
Europe
Colonoscopy
University Hospital Inselspital, Berne
Colonoscopy
05/22
05/22
Sai, Souken
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Misselwitz, Benjamin
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
SwissGut, NCT06191224: - The Healthy Swiss Microbiome

Recruiting
N/A
200
Europe
Benjamin Misselwitz
Healthy
07/25
07/25
NCT04976686: Low Carbohydrate Small Intestine Study

Terminated
N/A
13
Europe
Diet modification
Insel Gruppe AG, University Hospital Bern
Diet, Healthy
11/24
11/24
BeBiCo, NCT04447742: Bern Birth Cohort / Trajectory of Microbiota Maturation in Healthy Bern Infants - a Network Approach

Recruiting
N/A
250
Europe
Insel Gruppe AG, University Hospital Bern, University of Bern
Maturation of the Healthy Infant Intestinal Microbiota, Microbial Colonization, Nutrition Disorder, Infant, Milk Expression, Breast, Mental Health Disorder
03/28
03/35
NCT05800704: Support of Colonization Resistance of the Gut Microbiota with the Synbiotic Food Supplement Nagasin®

Active, not recruiting
N/A
49
Europe
Nagasin, maltodextrin
University of Zurich, Insel Gruppe AG, University Hospital Bern, Stadtspital Zürich, Kantonsspital Winterthur KSW, Luzerner Kantonsspital, Cantonal Hosptal, Baselland
C. Difficile Enteritis
03/25
03/25
NCT04978077: Networks of Bacterium-Metabolite Interactions in the Small Intestine

Terminated
N/A
120
Europe
Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)
Insel Gruppe AG, University Hospital Bern
Diet, Healthy, Microbial Colonization
11/24
11/24
COMMIT, NCT05702879: Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

Recruiting
N/A
240
Europe
Ozanimod, TNF Inhibitor, infliximab, adalimumab, etanercept, golimumab, and certolizumab., Steroids, Prednisolon, Vedolizumab, Ustekinumab
Insel Gruppe AG, University Hospital Bern, Bristol-Myers Squibb
Ulcerative Colitis
01/25
01/25
NCT04482452: Percentage Visualized Mucosa as a Marker for the Quality of Colonoscopy

Recruiting
N/A
500
Europe
Colonoscopy
University Hospital Inselspital, Berne
Colonoscopy
05/22
05/22
Sai, Souken
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27

Download Options